stars 1 stars 2 stars 3

ConserV is a late-stage vaccine development company focused on advancing safe and effective vaccines that protect against endemic and emergent infectious diseases. We have a pipeline of eight vaccines in pre-clinical and clinical development including broad-spectrum influenza*, broad-spectrum coronavirus, mosquito-borne diseases*, HIV, Hepatitis C, Hepatitis B, Rotavirus and Chagas. ConserV’s USP is the identification of antigens consisting of conserved regions of viral proteins containing a high number of REACTIVE T-cell epitopes with extensive HLA coverage. *Sub-licensed to Imutex Limited, a 51% owned subsidiary. hVIVO Services Limited own 49% of Imutex.

ConserV Bioscience Questions

Olga Pleguezuelos is the Chief Scientific Officer of ConserV Bioscience.

2 people are employed at ConserV Bioscience.

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users